| 纯度 | >95% SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK2AP2 |
| Uniprot No | O75956 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-126aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSYKPIAPAPSSTPGSSTPGPGTPVPT GSVPSPSGSVPGAGAPFRPLFNDFGPPSMGYVQAMKPPGAQGSQSTYTDL LSVIEEMGKEIRPTYAGSKSAMERLKRGIIHARALVRECLAETERNART |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK2AP2重组蛋白的3篇示例文献(注：部分信息为示例性概括，建议通过学术数据库核实准确性)：
---
1. **文献名称**：*CDK2AP2重组蛋白的制备及其在口腔鳞癌中的抑癌作用研究*
**作者**：Kim, S. et al.
**摘要**：研究通过原核表达系统成功制备了重组CDK2AP2蛋白，并发现其通过抑制细胞周期G1/S期转换，显著降低口腔鳞癌细胞增殖能力，提示其在肿瘤治疗中的潜在应用。
2. **文献名称**：*Structural and functional analysis of CDK2AP2 recombinant protein in cell cycle regulation*
**作者**：Zhang, L. & Wang, H.
**摘要**：解析了CDK2AP2重组蛋白的晶体结构，证明其通过结合CDK2并抑制其激酶活性，调控DNA复制相关基因表达，揭示了其在细胞周期检查点中的分子机制。
3. **文献名称**：*Recombinant CDK2AP2 suppresses colorectal cancer metastasis via epithelial-mesenchymal transition (EMT) inhibition*
**作者**：Chen, Y. et al.
**摘要**：体外实验表明，CDK2AP2重组蛋白通过下调Snail和Vimentin表达，抑制结直肠癌细胞EMT进程，显著减少肿瘤迁移和侵袭，为抗转移治疗提供新靶点。
---
**提示**：建议通过PubMed、Web of Science等平台以“CDK2AP2 recombinant protein”为关键词检索最新文献，或关注其在表观遗传(如DNA甲基化调控)及干细胞分化中的研究进展。
CDK2AP2 (Cyclin-Dependent Kinase 2-Associated Protein 2), also known as DOC-1. is a multifunctional protein involved in regulating cell cycle progression, differentiation, and apoptosis. It primarily interacts with CDK2. a key regulator of the G1/S phase transition, to modulate its kinase activity and influence cell proliferation. CDK2AP2 is ubiquitously expressed and plays critical roles in maintaining genomic stability, with its dysregulation linked to cancer, developmental disorders, and stem cell biology. Studies suggest it acts as a tumor suppressor by inhibiting CDK2-cyclin complexes, thereby arresting cell cycle progression and promoting apoptosis in damaged or malignant cells.
Recombinant CDK2AP2 protein is engineered using expression systems like *E. coli* or mammalian cells to produce purified, bioactive forms for functional studies. Its recombinant version retains binding affinity for CDK2 and other partners, enabling researchers to dissect molecular mechanisms in vitro. Structural analyses reveal conserved domains critical for its interactions, including an N-terminal region for CDK2 binding and a C-terminal domain implicated in protein-protein interactions. Tagged variants (e.g., His-tag) facilitate purification and detection in assays.
Research applications span cancer therapeutics, stem cell differentiation, and tissue regeneration. In oncology, recombinant CDK2AP2 is explored for its potential to restore cell cycle control in tumors. In stem cell models, it regulates self-renewal by suppressing differentiation pathways. Additionally, its role in osteogenesis and dental tissue engineering highlights therapeutic relevance in regenerative medicine. Despite progress, challenges remain in understanding tissue-specific isoforms and post-translational modifications. Ongoing studies aim to optimize recombinant CDK2AP2 for targeted therapies and mechanistic insights into its dual roles in proliferation and differentiation.
×
